Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (15)

2023

  1. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64

  2. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 291-298

2022

  1. PLCγ1/PKCθ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression

    Journal of Investigative Dermatology, Vol. 142, Núm. 5, pp. 1391-1400.e15

2021

  1. Mycosis fungoides and sézary syndrome: An integrative review of the pathophysiology, molecular drivers, and targeted therapy

    Cancers, Vol. 13, Núm. 8

2020

  1. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways

    British Journal of Dermatology, Vol. 182, Núm. 1, pp. 147-155

2018

  1. Mycosis fungoides progression could be regulated by microRNAs

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas

    Journal of Investigative Dermatology, Vol. 137, Núm. 1, pp. 197-206

2015

  1. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures

    Oncotarget, Vol. 6, Núm. 28, pp. 25452-25465

  2. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

    Haematologica

2014

  1. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases

    PLoS ONE, Vol. 9, Núm. 11

  2. PLCG1 mutations in cutaneous T-cell lymphomas

    Blood, Vol. 123, Núm. 13, pp. 2034-2043

2013

  1. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma

    Modern Pathology, Vol. 26, Núm. 2, pp. 171-181

  2. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

    Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2319-2330

  3. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

    Haematologica, Vol. 98, Núm. 1, pp. 57-64

  4. TCR-γ expression in primary cutaneous T-cell lymphomas

    American Journal of Surgical Pathology, Vol. 37, Núm. 3, pp. 375-384